• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Hans Joachim Schmoll, Eric Van Cutsem, +34 authors Andrés Cervantes
  • Medicine
  • Annals of oncology : official journal of the…
  • 2012 (First Published: 1 October 2012)
  • Colorectal cancer (CRC) is the most common tumour type in both sexes combined in Western countries. Although screening programmes including the implementation of faecal occult blood test andContinue Reading
  • Christophe Louvet, Roberto Labianca, +10 authors Aimery de Gramont
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2005 (First Published: 20 May 2005)
  • PURPOSE Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer. Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, we conducted a phaseContinue Reading
  • Marina Chiara Garassino, Olga Martelli, +17 authors Silvia Marsoni
  • Medicine
  • The Lancet. Oncology
  • 2013 (First Published: 1 September 2013)
  • BACKGROUND Erlotinib is registered for treatment of all patients with advanced non-small-cell lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are EGFRContinue Reading
  • Roberto Labianca, Bernard Nordlinger, Giordano Beretta, Antoine Brouquet, Anthony Cervantes
  • Medicine
  • Annals of oncology : official journal of the…
  • 2010 (First Published: 1 May 2010)
  • Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up R. Labianca, B. Nordlinger, G. D. Beretta, A. Brouquet & A. Cervantes On behalf of the ESMOContinue Reading
  • Volker Heinemann, Stefan Boeck, Axel Hinke, Roberto Labianca, Christophe Louvet
  • Medicine
  • BMC Cancer
  • 2007 (First Published: 1 December 2008)
  • BackgroundSingle-agent gemcitabine (GEM) is a standard treatment for advanced and metastatic pancreatic cancer. This study examines the question whether GEM-based combination chemotherapy can furtherContinue Reading
  • Daniel J Sargent, H. Samuel Wieand, +17 authors Aimery de Gramont
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2004 (First Published: 15 July 2004)
  • PURPOSE A traditional end point for colon adjuvant clinical trials is overall survival (OS), with 5 years demonstrating adequate follow-up. A shorter-term end point providing convincing evidence toContinue Reading